This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.0 (maple syrup urine disease) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | MSUD, branched-chain ketoaciduria, branched-chain alpha-keto acid dehydrogenase deficiency (BCKD deficiency), branched-chain alpha-ketoaciduria, Leucinosis |
| C. Adult onset | Likelihood of first onset in adulthood low (possible in intermittent and intermediate forms) — the classic form (classic MSUD) presents in the neonatal period; in the intermittent and intermediate forms, a first metabolic crisis in adulthood is possible during catabolic stress such as infection or surgery. |
| 1. History | 1954, first description by Menkes (maple syrup odor + neonatal neurological abnormalities) → 1960s, identification of BCKD enzyme deficiency → 1963, introduction of newborn screening in the US → 2000s, standardization of tandem mass screening. |
| 2. Causes | Mutations in the BCKDHA (E1α), BCKDHB (E1β), DBT (E2), and DLD (E3) genes → deficiency of the BCKD enzyme complex → accumulation of branched-chain amino acids (leucine, isoleucine, valine) and keto acids. |
| 3. Genetics | Autosomal recessive. BCKDHA (19q13.2), BCKDHB (6q14.1), DBT (1p21.2), DLD (7q31.1). High prevalence in the Old Order Mennonite population (c.1312T>A, 1/176). About 1/185,000 worldwide. |
| 4. General epidemiology | About 1/185,000 worldwide. Old Order Mennonites 1/176. Korea: about 1 in several hundred thousand by tandem mass screening. Equal in males and females. Classic form about 75%, other phenotypes about 25%. |
| 5. Pathophysiology | BCKD deficiency → accumulation of leucine, isoleucine, valine, and alpha-keto acids (BCKA) → neurotoxicity of leucine/ketoisocaproic acid (cerebral edema, impaired myelination) → fatal brain damage during acute metabolic crisis. |
| 6. Symptoms | Neonatal period: poor feeding, lethargy, vomiting, urine with maple syrup odor → without treatment, seizures, coma, death. Intermittent form: ataxia, lethargy, metabolic crisis with fever, infection, or surgery. Thiamine-responsive form: responds to vitamin B1 supplementation. |
| 7. Signs | Elevated blood leucine, isoleucine, and valine (especially leucine), presence of plasma alloisoleucine (pathognomonic sign of MSUD), increased urine BCKA, metabolic acidosis, elevated blood ammonia, white matter edema on brain MRI. |
| 8. Screening | Newborn tandem mass screening (elevated blood leucine + isoleucine + alloisoleucine, elevated C5 acylcarnitine). Included in the Korean national newborn screening panel. Early screening is very important in determining neurological prognosis. |
| 9. Diagnosis | Plasma amino acids (elevated leucine, presence of alloisoleucine), urine organic acids (alpha-ketoisocaproic acid, etc.), BCKD enzyme activity (leukocytes, fibroblasts), molecular genetics (BCKDHA, BCKDHB, DBT, DLD). |
| 10. Treatment | Special formula/diet restricted in branched-chain amino acids (especially leucine); acute phase: suppression of catabolism with high-dose glucose and insulin, hemodialysis. Thiamine-responsive form: thiamine 10–1,000 mg/day. Liver transplantation (curative treatment). |
| 11. Prognosis | Normal intelligence possible with newborn screening + early treatment. Neurological damage, intellectual disability, and motor impairment with recurrent metabolic crises or delayed diagnosis. After liver transplantation, relaxation of dietary restriction and prevention of metabolic crises. |
| 12. Prevention | Early newborn tandem mass screening, genetic counseling, PGT-M. Affected patients: implementation of an emergency protocol during catabolic states (fever, surgery, infection), adequate energy supply and protein restriction. |
| 13. References | Menkes JH et al. A sex-linked recessive disorder with retardation of growth, peculiar hair and focal cerebral and cerebellar degeneration. Pediatrics 1954;14:462 … and 9 other papers |
Maple syrup urine disease (MSUD) became known in 1954 when the American pediatrician John H. Menkes first reported cases in 4 siblings who showed progressive neurological deterioration from the neonatal period and whose urine had a distinctive maple syrup odor. Menkes initially described the disease as a syndrome associated with "retardation of growth with peculiar hair", and later the characteristic caramel- or maple syrup-like odor of the urine was recognized as the representative phenotype of the disease, giving it its current name. Around the same time, Westall et al. described similar cases.
Biochemical understanding advanced rapidly from 1957 through the 1960s. In 1957, Murray et al. confirmed that the disease is caused by blood accumulation of branched-chain amino acids (BCAA) — leucine, isoleucine, and valine and their alpha-keto acids. Subsequently, in the early 1960s, Colver et al. and Schmike et al. demonstrated that deficient activity of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC/BCKD) is the cause of MSUD.
In 1963, the US state of Oregon first introduced MSUD as a newborn screening item, and as tandem mass spectrometry (TMS) was subsequently applied to newborn screening (late 1990s to early 2000s), early diagnosis of MSUD was standardized in most developed countries. In Korea, tandem mass screening was officially included in the national newborn screening program from 2006, making early detection of MSUD possible.
On the treatment side, the development of BCAA-restricted special formula was an important milestone, and from the 1990s liver transplantation was introduced as a practical curative treatment option for MSUD. As results were reported showing that BCKD enzyme activity recovers to normal levels and dietary restrictions are greatly relaxed after liver transplantation, liver transplantation became established as a strong option for improving quality of life in patients with severe MSUD. Since the 2010s, research on hepatocyte transplantation and gene therapy has begun, and mRNA therapeutics and gene editing (CRISPR)-based approaches are also being explored at the preclinical stage.
What drew particular attention in MSUD epidemiological research was the very high prevalence (about 1/176) in the Old Order Mennonite population, explained by a founder effect and the high frequency of consanguineous marriage within the community. The BCKDHA gene founder mutation found in this population (c.1312T>A, p.Tyr438Asn) has provided an important resource for MSUD molecular research.
Maple syrup urine disease is caused by functional deficiency of the mitochondrial branched-chain alpha-keto acid dehydrogenase complex (BCKDC). This enzyme complex catalyzes the oxidative decarboxylation reaction, the second step in the metabolic pathway of the branched-chain amino acids (leucine, isoleucine, valine), converting the alpha-keto acids derived from each BCAA (alpha-ketoisocaproic acid, alpha-keto-beta-methylvaleric acid, alpha-ketoisovaleric acid) into their respective acyl-CoA derivatives.
BCKDC is a large multienzyme complex composed of three catalytic subunits and two regulatory enzymes. (1) E1 subunit (regulated by phosphorylation by BCKD kinase): a heterodimeric decarboxylase composed of two subunits, E1α (encoded by the BCKDHA gene, 19q13.2) and E1β (encoded by the BCKDHB gene, 6q14.1). (2) E2 subunit: dihydrolipoamide branched-chain acyltransferase, encoded by the DBT gene (1p21.2). (3) E3 subunit: dihydrolipoamide dehydrogenase, encoded by the DLD gene (7q31.1). Because the E3 subunit is shared with the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (OGDC), DLD gene mutations cause a combined phenotype (E3-deficient MSUD) in which MSUD is accompanied by dysfunction of the other two enzyme complexes.
When a pathogenic mutation occurs in any one of these 4 genes, BCKD enzyme complex activity falls, and BCAAs and their alpha-keto acids accumulate in blood and tissues. In particular, leucine and its keto acid, alpha-ketoisocaproic acid (KIC), are the most toxic and are the main cause of acute neurological damage and cerebral edema. Alloisoleucine is a non-physiological amino acid formed from alpha-keto-beta-methylvaleric acid, the keto acid of isoleucine, by reverse transamination from pyruvate, and is a pathological marker specific to MSUD.
MSUD phenotypes are classified by residual BCKD enzyme activity: (1) classic: residual activity 0–2%; (2) intermediate: 3–30%; (3) intermittent: normal to 30%, but worsens under stress; (4) thiamine-responsive: enzyme activity rises with high-dose thiamine (B1); (5) E3-deficient: DLD mutations, combined enzyme deficiency.
Maple syrup urine disease follows an autosomal recessive mode of inheritance. The status of the 4 causative genes (BCKDHA, BCKDHB, DBT, DLD) is as follows. BCKDHA (19q13.2, E1α subunit): the most common causative gene, with mutations identified in about 45% of MSUD patients worldwide. Various missense, nonsense, and splicing variants have been reported, including the Old Order Mennonite founder mutation c.1312T>A (p.Tyr438Asn). BCKDHB (6q14.1, E1β subunit): the second most common cause, accounting for about 35% of the total. DBT (1p21.2, E2 subunit): about 20%. DLD (7q31.1, E3 subunit): the rarest; DLD mutations overlap with features of pyruvate dehydrogenase deficiency and alpha-ketoglutarate dehydrogenase deficiency in addition to MSUD.
To date, hundreds of pathogenic variants have been reported in the BCKDHA, BCKDHB, DBT, and DLD genes; most are private variants, and concentration in specific ethnic groups is rare other than in the Old Order Mennonites. In East Asian populations (Korea, China, Japan), BCKDHA and BCKDHB variants are mainly reported. In Korea, genetic testing is performed after confirmation through newborn tandem mass screening, and a few studies on the specific Korean mutation spectrum of MSUD have been reported. Heterozygous carriers are asymptomatic, and carrier testing of family members is useful for future family planning.
The worldwide prevalence of maple syrup urine disease is estimated at about 1/185,000 based on newborn tandem mass screening results. However, it varies widely by region and ethnicity. In the Old Order Mennonite and Amish populations, the highest prevalence in the world, about 1/176, is observed. Relatively high prevalence has also been reported in regions where consanguineous marriage is common, such as Saudi Arabia.
Given autosomal recessive inheritance, the sex distribution is equal. The classic form accounts for about 75% of the total, and the rest are intermediate, intermittent, thiamine-responsive, and E3-deficient forms. In Korea, MSUD has been detected from birth since the introduction of tandem mass newborn screening in 2006, and the Korean prevalence is estimated to be similar to or lower than the world average. According to the rare disease statistics of the Health Insurance Review & Assessment Service (HIRA), the number of registered MSUD patients in Korea is in the tens, but it is estimated that more patients are actually under management after screening. With early detection and prompt dietary management, the number of patients with severe neurological damage has decreased greatly compared with the past.
The core pathogenesis of maple syrup urine disease is accumulation of branched-chain amino acids (BCAA) and their alpha-keto acids (BCKA) in blood and tissues due to BCKD enzyme complex deficiency. Among these, leucine and its alpha-keto acid, alpha-ketoisocaproic acid (KIC), have the strongest neurotoxicity. The following neurotoxic mechanisms have been proposed: (1) Competition for neutral amino acid transport into the brain: because leucine crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), elevated blood leucine competitively inhibits brain uptake of other essential amino acids (tyrosine, tryptophan, phenylalanine, etc.), causing reduced synthesis of neurotransmitters (dopamine, serotonin). (2) Mitochondrial dysfunction: KIC enters the mitochondrial matrix of cells, competitively inhibits the pyruvate dehydrogenase complex (PDC), and impairs TCA cycle function through inhibition of glutamate dehydrogenase. (3) Impaired myelination: accumulated leucine and keto acids interfere with enzyme pathways needed for myelin lipid synthesis, inhibiting normal brain myelination in the neonatal period. (4) Cerebral edema: acute cerebral edema develops due to the osmotic activity of leucine and impaired energy metabolism, and this is the most direct cause of death in acute metabolic crises. Alloisoleucine is an MSUD-specific amino acid; higher blood levels are associated with acute-phase neurological damage, so it is used to assess treatment response and severity.
The clinical symptoms of maple syrup urine disease vary with phenotype, and the classic form (classic MSUD) is the most severe.
Neonatal symptoms of classic MSUD: infants generally appear normal immediately after birth, but symptoms begin to appear from 2–5 days of age. Early symptoms include poor feeding, lethargy, irritability, and urine and cerumen with a characteristic maple syrup or caramel odor. Within a few days, intermittent apneic episodes, metabolic ketoacidosis, hyperammonemia (intermittent), and hypoglycemia appear, and without treatment the condition progresses to seizures, coma, and acute cerebral edema, leading to death.
Intermittent and intermediate MSUD: patients are usually asymptomatic or have only mild symptoms, but when catabolic stress such as fever, infection, surgery, or childbirth occurs, acute metabolic crises such as ataxia, lethargy, vomiting, metabolic ketoacidosis, and cerebral edema suddenly develop. Without catabolic stress, normal life is possible, so diagnosis is sometimes delayed into adulthood. Thiamine-responsive MSUD: with high-dose thiamine (vitamin B1), BCKD enzyme activity rises and symptoms improve. In this phenotype, thiamine 100–1,000 mg/day is used as part of long-term treatment. E3-deficient MSUD: in addition to MSUD symptoms, lactic acidosis, hypoglycemia, and liver dysfunction are present. When neurological damage is severe, developmental delay, intellectual disability, motor impairment, and learning disabilities may remain as long-term sequelae.
Acute-phase test findings: plasma amino acid analysis shows marked elevation of leucine (rising from a normal 50–200 μmol/L to 1,000 μmol/L or more), isoleucine, and valine. In particular, the presence of alloisoleucine in blood is a highly specific marker of MSUD and is not detected in healthy people. Urine organic acid analysis shows increased BCKA such as alpha-ketoisocaproic acid, alpha-ketoisovaleric acid, and alpha-keto-beta-methylvaleric acid. On tandem mass screening, blood C5-acylcarnitine (a mixture of 2-methylbutyrylcarnitine + isovalerylcarnitine, or a combined elevation of leucine and isoleucine) is increased.
Metabolic abnormalities: metabolic ketoacidosis (reduced pH, increased anion gap), low blood glucose (hypoglycemia), and moderately elevated blood ammonia may appear in the acute phase. Brain MRI: in the acute phase, findings of metabolic cerebral edema are characteristic, with restricted diffusion (high DWI signal, low ADC signal) and T2 hyperintensity in the cerebral and cerebellar white matter, brainstem, and basal ganglia. When long-term sequelae are present, white matter signal abnormalities, reduced brain volume, and basal ganglia signal abnormalities are observed. BCKD enzyme activity can be measured in leukocytes or skin fibroblasts and is reduced to 0–2% of normal in the classic form and 3–30% in the intermediate form.
Maple syrup urine disease is a major target disease of newborn tandem mass spectrometry (TMS) screening. In Korea, MSUD has been included in the national newborn screening program since 2006, and newborn heel prick blood is collected within 48–72 hours of birth and tested as a dried blood spot (DBS).
The key indicators for MSUD screening are as follows: (1) Elevated combined concentration of blood leucine (Leu) + isoleucine (Ile): on tandem mass spectrometry these two amino acids have the same molecular weight and are measured together. Screening is positive when the normal reference value is exceeded. (2) Elevated C5-acylcarnitine (C5-AC): a combined peak of 2-methylbutyrylcarnitine and isovalerylcarnitine, which may be elevated in MSUD but requires differentiation from isovaleric acidemia. (3) Alloisoleucine is often difficult to measure directly by TMS, so it is confirmed by plasma amino acid chromatography in confirmatory testing. Immediately referring screen-positive newborns to a specialist and starting confirmatory testing and dietary restriction as quickly as possible is decisive for neurological prognosis. In premature infants or ill newborns admitted to the neonatal intensive care unit (NICU), false positives may increase, so caution is needed in interpretation.
Confirmation of MSUD proceeds through the following steps. (1) Plasma amino acid analysis (ion-exchange chromatography): marked elevation of leucine, isoleucine, and valine and the presence of alloisoleucine are highly specific for the diagnosis of MSUD. Quantitative values are used for severity assessment and treatment monitoring. (2) Urine organic acid analysis (GC-MS): increased alpha-ketoisocaproic acid, alpha-ketoisovaleric acid, and alpha-keto-beta-methylvaleric acid are confirmed. Ketone bodies (a marker of ketoacidosis) are also increased. (3) BCKD enzyme activity measurement: BCKD activity is measured directly in peripheral blood leukocytes or skin fibroblasts, allowing phenotype classification (classic, intermediate, intermittent). Enzyme activity before and after thiamine administration can be compared to determine thiamine responsiveness. (4) Molecular genetic testing: NGS panel testing of the BCKDHA, BCKDHB, DBT, and DLD genes to identify pathogenic variants and predict phenotype. Confirmed when pathogenic variants are identified in both alleles. (5) Brain MRI: assessment of acute-phase neurological involvement and confirmation of long-term sequelae. (6) Differential diagnosis: isovaleric acidemia (IVA) — similar with elevated C5-AC but no alloisoleucine; other organic acidemias. Differentiation is also needed from other causes of neonatal lethargy and poor feeding (sepsis, neonatal seizures, etc.).
Treatment of maple syrup urine disease is divided into acute-phase treatment and long-term maintenance treatment.
Treatment of acute metabolic crisis: (1) Immediate cessation of BCAA (especially leucine) intake: protein intake containing BCAA is temporarily stopped by the oral or parenteral route. (2) High-energy glucose and insulin administration: sufficient calories (carbohydrate + fat) are provided to suppress endogenous protein catabolism and reduce BCAA catabolism. Giving insulin (0.1 unit/kg/hour) together enhances the anticatabolic effect. (3) Hemodialysis or peritoneal dialysis: when blood leucine is very high (>2,000 μmol/L) and neurological symptoms are severe, rapid removal of BCAA by hemodialysis is needed. (4) Intravenous administration of a BCAA-free amino acid mixture (essential amino acid mixture, Leu-free formula) to induce an anabolic state.
Long-term maintenance treatment: BCAA-restricted special formula and a low-protein diet are the foundation. Leucine is allowed only at the minimum supply of the body's requirement (the minimum needed for growth and development), and because valine and isoleucine become relatively deficient during treatment, separate supplementation is often needed. The goal is to maintain blood leucine between 100 and 200 μmol/L. During catabolic stress (fever, infection, surgery), temporary protein restriction + sufficient energy supply are implemented according to an emergency protocol. In the thiamine-responsive form, oral thiamine 10–1,000 mg/day can increase BCKD enzyme activity and allow dietary restriction to be relaxed. Liver transplantation is currently the most fundamental treatment option for MSUD; after transplantation, BCKD enzyme activity is restored in the liver, and BCAA dietary restriction becomes largely unnecessary. Because BCKD activity in the brain is not restored even after liver transplantation, blood leucine monitoring is still needed during catabolic stress.
The prognosis of maple syrup urine disease varies greatly with the timing of diagnosis, the adequacy of treatment, and the phenotype. When detected early by newborn tandem mass screening and when strict dietary management and prevention of metabolic crises are achieved early in the course (within the first 2 weeks of life), normal intelligence and neurological development are possible. According to long-term follow-up studies, MSUD patients who received early treatment and have high dietary adherence can have normal schooling, work, and social activities. However, in the classic form, delayed diagnosis (7 days or more without treatment) or recurrent acute metabolic crises are the main risk factors for irreversible neurological damage, intellectual disability, and motor impairment.
In the long term, reduced quality of life due to the difficulty of dietary management (strict BCAA-restricted diet, dependence on special formulas), mental health problems (anxiety, depression), and nutritional deficiencies (zinc, selenium, essential fatty acids, etc.) may appear as treatment-related complications. After liver transplantation, most dietary restrictions are relaxed and quality of life improves markedly. Overall, the life expectancy of well-managed MSUD patients is normal or near normal, and the prognosis is better in patients with the thiamine-responsive and intermittent forms.
Primary prevention of maple syrup urine disease is achieved through genetic counseling and preimplantation and prenatal genetic testing. Each pregnancy of two carrier parents carries a 25% risk of an affected child, and accordingly PGT-M (preimplantation genetic testing) or prenatal DNA testing (chorionic villus sampling/amniocentesis) is possible.
The most important measure of secondary prevention is early performance of newborn tandem mass screening. In Korea, testing within 48–72 hours of birth is standardized, and when the result is positive, the infant is immediately referred to a specialist to confirm the diagnosis and start treatment. Because neurological prognosis is better the earlier treatment begins, it is sometimes recommended to start preventive dietary measures even before the results are confirmed when screening is positive. In affected patients, in all catabolic stress situations such as fever, infection, surgery, and childbirth, dietary adjustment (stricter BCAA restriction, sufficient energy supply) is implemented immediately according to a pre-established emergency protocol. Patients are taught to carry such an emergency protocol card at all times, and maintaining a hotline with the care team is important. Family education, education of schools and childcare facilities, and ongoing collaboration with dietitians are provided as tertiary prevention.